BioSpace News Archive

Kintai Therapeutics, a pioneer in unlocking the power of the human enteric signaling network and its signals throughout the body to combat disease and promote health, announced today that it is in the initial stages of combining its operations and talent with fellow Flagship Labs-founded company Senda Biosciences.

Domain Associates and Catalys Pacific today announced the launch of Exalys Therapeutics Inc. with the closing of a $15 million Series A financing and the licensing of a platform of next-generation EP4 receptor antagonists from Eisai Co. Ltd. in Japan.

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT) for hard-to-treat cancers, has announced an agreement with RaySearch Laboratories for Raystation support of the TLS Alphabeam™ System.

Lincotek Additive, the Additive Solutions Provider, has recently completed its brand new, state-of-the-art Additive Production Center for medical devices in its Trento facility, by installing a new high-vacuum furnace and a validated heat treatment process, specifically designed for 3D-printed titanium parts.

Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Daniella Beckman to its Board of Directors. The appointment of Ms. Beckman, an experienced biotech finance leader who currently serves as Chief Financial Officer at Tango Therapeutics, follows the hiring of Christopher Slapak, MD, as Chief Medical Officer and the com

Adagio Therapeutics Launches With $50M Series A Financing to Advance the Development of Best-in-Class, Broadly Neutralizing Antibodies for Coronavirus Treatment and Prophylaxis -Financing led by Polaris Partners and Mithril Capital, and includes investments by Fidelity funds, OrbiMed, M28 Capital, GV, and others- -Antibodies engineered to offer best-in-class, long-term protection against SARS-CoV-2 with utility against future coronaviruses-

Invetx, a pioneer in protein-based therapeutics for animal health, announced today the launch of its antibody-based platform for the discovery and development of novel medicines for animal health

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Invetx, a pioneer in protein-based therapeutics for animal health, today announced a partnership for the engineering and optimization of novel antibodies for the treatment of serious diseases in dogs and cats. “Many dis

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the filing of the pivotal ENVASARC protocol with the U.S. Food and Drug Administration (FDA) as

Atreca, Inc. announced the pricing of its previously announced underwritten public offering of 7,031,250 shares of its Class A Common Stock and 781,250 shares of its Class B Common Stock, each at a price to the public of $16.00 per share.